C-Reactive Protein (CRP) Test Market Share, Growth Opportunities and Analysis by Application till 2028 “C–Reactive protein is an immunoprotein, which is synthesized in the liver and it helps in activation of all the complement systems. The C–Reactive protein test measures the levels of C-Reactive protein in the body and has the capability to find out if the person is suffering from heart attacks or strokes.” Global C–Reactive Protein (CRP) Test Market is anticipated to exhibit a rise in the CAGR during its forecast period. C–Reactive protein is an immunoprotein, which is synthesized in the liver and it helps in activation of all the complement systems. The C–Reactive protein test measures the levels of C-Reactive protein in the body and has the capability to find out if the person is suffering from heart attacks or strokes. Under average circumstances, CRP is stated in very low levels, but it has the efficiency to increase 1,000 folds in the span of 24 hours of tissue damage or infection. It has been witnessed that there is a surge in number of incidences of inflammatory disorders such as cardiovascular disorders and cancer infections. This sudden rise is influencing the growth of the C–Reactive protein test market massively. Along with this, another factor that is playing a major role and is growing the market is the prevalence of endometriosis in women. Looking at this wide-ranging market, there is still a lack of public awareness for CRP tests, which is one of the major restraining factor for the market. But due to the favorable policies of the government and more of investments in its R&D, this market is expected to grow rapidly in the near future. Browse Full Research Report @ https://www.millioninsights.com/industry-reports/c-reactive-protein-crp-test-market-study The C–Reactive protein test market is segmented on the basis of assay type (immunoturbidimetric assay, ELISA, chemiluminescence immunoassay), detection range (hs – CRP, conventional CRP, cCRP), disease area (cardiovascular diseases, cancer, rheumatoid, arthritis, inflammatory bowel diseases, endometriosis, lupus), end user (clinics, hospitals,